Gliobststoma (GBM) is a highly aggressive brain tumor that is resistant to many conventional cancer therapies. The kinase mTOR induces pathways that are aberrantly activated in GBM. However, mTOR inhibitors have not shown much promise for treating GBM.
A new study in the Journal of Clinical Investigation indicates that mTOR inhibitor resistance in GBM is likely the result of compensatory glutamine metabolism.
Kazuhiro Tanaka and colleagues at Kobe University determined that glutaminase and glutamine levels increase in GBM cells and xenografts in response to mTOR inhibition. Combined inhibition of glutatminase and mTOR suppressed growth of GBM tumor xenografts.
Moreover, in patients with GBM, glutamine metabolism was increased in tumor tissue compared to noncancerous areas in the brain.
Together, these results suggest that combined targeting of mTOR and glutamine metabolism should be further explored as a therapeutic strategy for GBM.
Explore further: Glioblastoma: Study ties three genes to radiation resistance in recurrent tumors
More information: Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR-targeted therapies, J Clin Invest. 2015;125(4):1591–1602. DOI: 10.1172/JCI78239
Abstract
The mechanistic target of rapamycin (mTOR) is hyperactivated in many types of cancer, rendering it a compelling drug target; however, the impact of mTOR inhibition on metabolic reprogramming in cancer is incompletely understood. Here, by integrating metabolic and functional studies in glioblastoma multiforme (GBM) cell lines, preclinical models, and clinical samples, we demonstrate that the compensatory upregulation of glutamine metabolism promotes resistance to mTOR kinase inhibitors. Metabolomic studies in GBM cells revealed that glutaminase (GLS) and glutamate levels are elevated following mTOR kinase inhibitor treatment. Moreover, these mTOR inhibitor–dependent metabolic alterations were confirmed in a GBM xenograft model. Expression of GLS following mTOR inhibitor treatment promoted GBM survival in an α-ketoglutarate–dependent (αKG-dependent) manner. Combined genetic and/or pharmacological inhibition of mTOR kinase and GLS resulted in massive synergistic tumor cell death and growth inhibition in tumor-bearing mice. These results highlight a critical role for compensatory glutamine metabolism in promoting mTOR inhibitor resistance and suggest that rational combination therapy has the potential to suppress resistance.
Medical Xpress on facebook
Related Stories
Glioblastoma: Study ties three genes to radiation resistance in recurrent tumors
A new study identifies three genes that together enable a lethal form of brain cancer to recur and progress after radiation therapy.
A thought-provoking new therapeutic target for brain cancer?
Glioblastoma multiforme (GBM) is the most common of all malignant brain tumors that originate in the brain. Patients with GBM have a poor prognosis because it is a highly aggressive form of cancer that is commonly resistant ...
New target identified for potential brain cancer therapies
Researchers from Virginia Commonwealth University (VCU) Massey Cancer Center and the VCU Institute for Molecular Medicine (VIMM) have identified a new protein-protein interaction that could serve as a target for future therapies ...
Aberrant mTOR signaling impairs whole body physiology
The protein mTOR is a central controller of growth and metabolism. Deregulation of mTOR signaling increases the risk of developing metabolic diseases such as diabetes, obesity and cancer. In the current issue ...
Researchers find promise in new treatments for glioblastma multiforme
Glioblastma multiforme (GBM) is one of the most lethal primary brain tumors, with median survival for these patients only slightly over one year. Researchers at Boston University School of Medicine (BUSM), in collaboration ...
Recommended for you
Metformin and vitamin D3 show impressive promise in preventing colorectal cancer
The concept was simple: If two compounds each individually show promise in preventing colon cancer, surely it's worth trying the two together to see if even greater impact is possible.
How to get smarter on pills for seniors
Open the medicine cabinet of a senior and you're likely to find scores of pill bottles. Physicians are often unaware of all the medications a patient is taking, which can result in unnecessary additional prescriptions, non-prescription ...
Combining the old and new to kill cancer cells
A team of Singapore based scientists have found that pairing a new approach with an old drug may be an effective approach to treat common cancers. In a landmark study, Professor David Virshup and Dr. Jit ...
Detecting cancer cells in blood can give an early warning of treatment failure
A blood test that measures the number of cells shed from prostate tumours into the bloodstream can act as an early warning sign that treatment is not working, a major new study shows.
Stress granules ease the way for cancer metastasis
Tumors that produce more stress granules are more likely to metastasize, according to a study published in The Journal of Cell Biology. The results suggest that drugs to inhibit the formation of these struct ...
Sweeping prostate cancer review upends widely held belief on radiation after surgery
Important news for men receiving treatment for prostate cancer: Two new studies from the University of Virginia School of Medicine have upended the widely held view that it's best to delay radiation treatment ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
Gliobststoma (GBM) is a highly aggressive brain tumor that is resistant to many conventional cancer therapies. The kinase mTOR induces pathways that are aberrantly activated in GBM. However, mTOR inhibitors have not shown much promise for treating GBM.
A new study in the Journal of Clinical Investigation indicates that mTOR inhibitor resistance in GBM is likely the result of compensatory glutamine metabolism.
Kazuhiro Tanaka and colleagues at Kobe University determined that glutaminase and glutamine levels increase in GBM cells and xenografts in response to mTOR inhibition. Combined inhibition of glutatminase and mTOR suppressed growth of GBM tumor xenografts.
Moreover, in patients with GBM, glutamine metabolism was increased in tumor tissue compared to noncancerous areas in the brain.
Together, these results suggest that combined targeting of mTOR and glutamine metabolism should be further explored as a therapeutic strategy for GBM.
Explore further: Glioblastoma: Study ties three genes to radiation resistance in recurrent tumors
More information: Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR-targeted therapies, J Clin Invest. 2015;125(4):1591–1602. DOI: 10.1172/JCI78239
Abstract
The mechanistic target of rapamycin (mTOR) is hyperactivated in many types of cancer, rendering it a compelling drug target; however, the impact of mTOR inhibition on metabolic reprogramming in cancer is incompletely understood. Here, by integrating metabolic and functional studies in glioblastoma multiforme (GBM) cell lines, preclinical models, and clinical samples, we demonstrate that the compensatory upregulation of glutamine metabolism promotes resistance to mTOR kinase inhibitors. Metabolomic studies in GBM cells revealed that glutaminase (GLS) and glutamate levels are elevated following mTOR kinase inhibitor treatment. Moreover, these mTOR inhibitor–dependent metabolic alterations were confirmed in a GBM xenograft model. Expression of GLS following mTOR inhibitor treatment promoted GBM survival in an α-ketoglutarate–dependent (αKG-dependent) manner. Combined genetic and/or pharmacological inhibition of mTOR kinase and GLS resulted in massive synergistic tumor cell death and growth inhibition in tumor-bearing mice. These results highlight a critical role for compensatory glutamine metabolism in promoting mTOR inhibitor resistance and suggest that rational combination therapy has the potential to suppress resistance.
Medical Xpress on facebook
Related Stories
Glioblastoma: Study ties three genes to radiation resistance in recurrent tumors
A new study identifies three genes that together enable a lethal form of brain cancer to recur and progress after radiation therapy.
A thought-provoking new therapeutic target for brain cancer?
Glioblastoma multiforme (GBM) is the most common of all malignant brain tumors that originate in the brain. Patients with GBM have a poor prognosis because it is a highly aggressive form of cancer that is commonly resistant ...
New target identified for potential brain cancer therapies
Researchers from Virginia Commonwealth University (VCU) Massey Cancer Center and the VCU Institute for Molecular Medicine (VIMM) have identified a new protein-protein interaction that could serve as a target for future therapies ...
Aberrant mTOR signaling impairs whole body physiology
The protein mTOR is a central controller of growth and metabolism. Deregulation of mTOR signaling increases the risk of developing metabolic diseases such as diabetes, obesity and cancer. In the current issue ...
Researchers find promise in new treatments for glioblastma multiforme
Glioblastma multiforme (GBM) is one of the most lethal primary brain tumors, with median survival for these patients only slightly over one year. Researchers at Boston University School of Medicine (BUSM), in collaboration ...
Recommended for you
Metformin and vitamin D3 show impressive promise in preventing colorectal cancer
The concept was simple: If two compounds each individually show promise in preventing colon cancer, surely it's worth trying the two together to see if even greater impact is possible.
How to get smarter on pills for seniors
Open the medicine cabinet of a senior and you're likely to find scores of pill bottles. Physicians are often unaware of all the medications a patient is taking, which can result in unnecessary additional prescriptions, non-prescription ...
Combining the old and new to kill cancer cells
A team of Singapore based scientists have found that pairing a new approach with an old drug may be an effective approach to treat common cancers. In a landmark study, Professor David Virshup and Dr. Jit ...
Detecting cancer cells in blood can give an early warning of treatment failure
A blood test that measures the number of cells shed from prostate tumours into the bloodstream can act as an early warning sign that treatment is not working, a major new study shows.
Stress granules ease the way for cancer metastasis
Tumors that produce more stress granules are more likely to metastasize, according to a study published in The Journal of Cell Biology. The results suggest that drugs to inhibit the formation of these struct ...
Sweeping prostate cancer review upends widely held belief on radiation after surgery
Important news for men receiving treatment for prostate cancer: Two new studies from the University of Virginia School of Medicine have upended the widely held view that it's best to delay radiation treatment ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
0 comments:
Post a Comment